Cancer Treatment Reviews
Volume 31 , Pages S3-S9 , 2005

Clinical development of fulvestrant (‘Faslodex’)

  • Anthony Howell

      Affiliations

    • CRUK Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 161 446 8037; fax: + 44 161 446 8000.
    • ,
  • Paul Abram

      Affiliations

    • Belvoir Park Hospital, Belfast, UK

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0305-7372(05)00140-4

doi: 10.1016/j.ctrv.2005.08.010

Cancer Treatment Reviews
Volume 31 , Pages S3-S9 , 2005

Article Tools

* Image Usage & Resolution